Wogonoside is widely studied for its anti-inflammatory and neuroprotective properties, making it a compound of interest in the development of treatments for neurological disorders such as Alzheimer's and Parkinson’s disease. It has shown potential in reducing oxidative stress and inhibiting the activation of microglial cells, which play a key role in neuroinflammation. In cancer research, wogonoside exhibits antiproliferative effects against various tumor cell lines, including liver, breast, and colorectal cancers. It induces apoptosis and cell cycle arrest, suggesting its role as a supportive agent in oncology therapeutics. It also demonstrates hepatoprotective activity, helping to protect liver cells from damage caused by toxins and reducing markers of liver injury in preclinical models. Due to its ability to modulate signaling pathways like NF-κB and MAPK, wogonoside is considered a promising candidate for drug development in chronic inflammatory and metabolic diseases. Additionally, it has been explored for its antiviral effects, particularly in inhibiting certain strains of influenza and hepatitis viruses, highlighting its broad therapeutic potential.